Answers are grounded in this paper and cite their sources.
INTRODUCTION: Bronchiolitis is a major public health problem worldwide. However, no effective treatment strategies are available, other than supportive care. AREAS COVERED: Although bronchiolitis has been considered a single disease diagnosed based on clinical characteristics, emerging evidence supports both clinical and pathobiological heterogeneity. The characterization of this heterogeneity supports the concept that bronchiolitis consists of multiple phenotypes or consistent grouping of characteristics. Expert commentary: Using unbiased statistical approaches, multidimentional clinical characteristics will derive bronchiolitis phenotypes. Furthermore, molecular and systems biology approaches will, by linking pathobiology to phenotype, identify endotypes. Large cohort studies of bronchiolitis with comprehensive clinical characterization and system-wide profiling of the '-omics' data (e.g., host genome, transcriptome, epigenome, viral genome, microbiome, metabolome) should enhance our ability to molecularly understand these phenotypes and lead to more targeted and personalized approaches to bronchiolitis treatment.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: